Reviewing Common Themes in Double Patenting. James Wilson, SPE 1624 TC

Similar documents
We Innovate Healthcare 1

Restriction: Definition & Characteristics A tool used by the USPTO to limit the substantive examination of a patent application to a single invention

Navigating through the Obviousness-Type Double Patenting Minefield Landslide Vol. 10, No. 3 January/February 2018

Restriction. AIPLA Practical Patent Prosecution Alexandria, VA August Brian R. Stanton, Ph.D. US DOC/HHS (Ret.)

Double Patenting: Defeating Double Patenting Rejections and Avoiding Terminal Disclaimers

Rule 130 Declarations for First-Inventor-to-File Applications

Patents and the Protection of Proprietary Biotechnology Information

USPTO Final Rule Changes for Continuations and Claims. John B. Pegram Ronald C. Lundquist August 30, 2007

Gilead And Potential Unforeseen Consequences: Part 1

New Patent Application Rules Set to Take Effect November 1, 2007

Advanced Topics in Double Patenting

Double Patenting: Defeating Rejections and Avoiding Terminal Disclaimers

United States Patent and Trademark Office Registration Examination for Patent Attorneys and Agents October 16, Morning Session Model Answers

Chapter 1400 Correction of Patents

Patent Prosecution Update

CORRECTION OF ISSUED PATENTS

Prosecuting Patent Applications: Establishing Unexpected Results

EFFECTIVE DATES OF THE VARIOUS RULES AND REQUIREMENTS

Restriction Requirements

OLIVE & OLIVE, P.A. INTELLECTUAL PROPERTY LAW

CIP S ARE USELESS BY LOUIS J. HOFFMAN HOFFMAN PATENT FIRM PHOENIX, ARIZONA NAPP 2005 CONVENTION

Changes To Implement the First Inventor To File Provisions of the Leahy-Smith America Invents Act Final Rules

First Inventor to File: Proposed Rules and Proposed Examination Guidelines

PATENT DISCLOSURE: Meeting Expectations in the USPTO

Patent Exam Fall 2015

Chemical Patent Practice. Course Syllabus

Basic Patent Information from the USPTO (Redacted) November 15, 2007

BUSINESS METHOD PATENTS IN THE UNITED STATES: A LEGISLATIVE RESPONSE

Patent Prosecution Under The AIA

In re Metoprolol Succinate Obviousness-Type Double Patenting Walter B. Welsh St. Onge Steward Johnston & Reens LLC Stamford, Connecticut

(SUCCESSFUL) PATENT FILING IN THE US

US Patent Prosecution Duty to Disclose

The Patent Examination Manual. Section 10: Meaning of useful. Meaning of useful. No clear statement of utility. Specific utility

The patentability criteria for inventive step I nonobviousness. The Groups are invited to answer the following questions under their national laws:

Information Disclosure Statements 2017 BIRCH, STEWART, KOLASCH & BIRCH, LLP

Patent Resources Group. Chemical Patent Practice. Course Syllabus

PATENT REFORM. Did Patent Reform Level the Playing Field for Foreign Entities? 1 Leahy-Smith America Invents Act, Pub. L. No.

November Common Sense Approach to Obviousness. g Obvious to Try. g Obviousness-Type Double Patenting

patents grant only the right to stop others from making, using and selling the invention

Chapter 2300 Interference Proceedings

The use of prosecution history in post-grant patent proceedings

United States Patent and Trademark Office Registration Examination for Patent Attorneys and Agents April 18, Morning Session Model Answers

U.S. Design Patent Protection. Finnish Patent Office April 10, 2018

Introduction. 1 These materials are public information and have been prepared solely for educational and entertainment purposes to contribute

35 U.S.C. 135 Gateway to Priority and Derivation Determinations by the BPAI

Biological Deposits MPEP and 37 C.F.R Gary Benzion Supervisory Patent Examiner Technology Center 1600 Art Unit 1637

A (800) (800)

1~~~rew OFFICE OF PETITIONS RELEVANT BACKGROUND OCT UNITED STATES PATENT AND TRADEMARK OFFICE

(Serial No. 29/253,172) IN RE TIMOTHY S. OWENS, SHEILA M. KELLY, ROBERT M. LYNCH, IV, JASON C. CAMPBELL, and PHILIP E.

US Design Patents for Graphical User Interfaces in the US. Margaret Polson Polson Intellectual Property Law, PC

United States Court of Appeals for the Federal Circuit

Key Words Glossary Contents

Please find below and/or attached an Office communication concerning this application or proceeding.

Art. 123(2) EPC ADDED MATTER A US Perspective. by Enrica Bruno Patent Attorney. Steinfl & Bruno LLP Intellectual Property Law

Patent Law & Nanotechnology: An Examiner s Perspective. Eric Woods MiRC Technical Staff

Patentable Inventions Versus Unpatentable: How to Assess and Decide

IP Innovations Class

Patents. What is a Patent? 11/16/2017. The Decision Between Patent and Trade Secret Protection

Delain Law Office, PLLC

America Invents Act (AIA) The Patent Reform Law of 2011 Initial Summary

United States. Edwards Wildman. Author Daniel Fiorello

Dynamic Drinkware, a Technical Trap for the Unwary

Post-Allowance Prosecution: The End Game That Goes On To The End

Changes to Implement the First Inventor to File Provisions of the Leahy-Smith. AGENCY: United States Patent and Trademark Office, Commerce.

Tips On Maximizing Patent Term Adjustment

The petition to change patent term adjustment determination under 35 U.S.C. 154(b) from 153 days to a 318 days is DENIED.

Practice for Patent Application

PATENTS TRADEMARKS COPYRIGHTS TRADE SECRETS ZIOLKOWSKI PATENT SOLUTIONS GROUP, SC INTELLECTUAL PROPERTY ATTORNEYS. Patent Process FAQs

For a patent to be valid, it needs to be useful, novel, nonobvious, and adequately

John Doll Commissioner for Patents. February 1, 2006

Paper 34 Tel: Entered: June 22, 2016 UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD

Preparing A Patent Application

Innovation Act (H.R. 9) and PATENT Act (S. 1137): A Comparison of Key Provisions

~O~rE~ OFFICE OF PETITIONS JAN Haisam Yakoub 2700 Saratoga Place #815 Ottawa ON K1T 1W4 CA CANADA

GLOSSARY OF INTELLECTUAL PROPERTY TERMS

Chapter 1300 Allowance and Issue

Prosecution pt. 1; Infringement pt. 1; ST: Interviewing Patent Applications

Information and Guidelines Concerning the Patent and Copyright Process at East Tennessee State University

Intellectual Property Primer. Tom Utley, PhD, CLP Licensing Officer Patent Agent

Stephen Walsh [prepared for Patenting People, Nov , 2006, Benjamin N. Cardozo School of Law]

First-Inventor-to-File

USPTO Implementation of the America Invents Act. Janet Gongola Patent Reform Coordinator Direct dial:

United States Court of Appeals for the Federal Circuit

United States Court of Appeals for the Federal Circuit

Change in Procedure Relating to an Application Filing Date

INTELLECTUAL PROPERTY LAWS AMENDMENT (RAISING THE BAR ACT) 2012

Chapter 1900 Protest Protest Under 37 CFR [R ] How Protest Is Submitted

Patent Prosecution and Joint Ownership of United States Patents

Inventorship. July 13, Christina Sperry, Member

Intellectual Property. EMBL Summer Institute 2010 Dusty Gwinn WVURC

America Invents Act H.R (Became Law: September 16, 2011) Michael K. Mutter Birch, Stewart, Kolasch & Birch October 11-12, 2011

Good afternoon, Please acknowledge receipt by return . Thank you, Erin Sheehan Policy Assistant

Winning a Non-Obviousness Case at the Board

The content is solely for purposes of discussion and illustration, and is not to be considered legal advice.

The America Invents Act : What You Need to Know. September 28, 2011

No. 30 of Patents and Industrial Designs Act Certified on: 19/1/2001.

Chapter 1800 Patent Cooperation Treaty

PATENT LAW DEVELOPMENTS

United States Patent and Trademark Office Registration Examination for Patent Attorneys and Agents April 18, Afternoon Session Model Answers

COMPARATIVE STUDY REPORT TRILATERAL PROJECT 12.4 INVENTIVE STEP - 1 -

Transcription:

Reviewing Common Themes in Double Patenting James Wilson, SPE 1624 TC 1600 James.Wilson@uspto.gov 571-272-0661

What is Double Patenting (DP)? Statutory DP Based on 35 USC 101 An applicant (or assignee) is prohibited from obtaining two patents for same invention Nonstatutory DP (e.g., obviousness-type) Based on a judicially created doctrine An applicant (or assignee) is prohibited from obtaining a patent for an invention that is an obvious variation of an invention for which the applicant (or assignee) already has a patent (unless certain conditions are met, i.e., Terminal Disclaimer filed) 9/10/2015 2

The Purpose Behind the Policy Double Patenting Prevents unjustified extension of rights Prevents harassment from multiple owners. In re Van Ornum, 686 F.2d 937, 944-48, 214 USPQ 761, 767-70 (CCPA 1982). After expiration, public should be able to: Freely use the claimed invention Freely use obvious modifications of the claimed invention 9/10/2015 3

Graphical Representation of an Example of Unjustified Extension Original Application Second Application By Applicant Or Assignee Filing Date Filing Date Issue Date Possible Unjust Extension Of Original Patent Term Issue Date Patent Expiration Date Patent Expiration Date NO Free Public Use Of the Invention and Obvious Modifications Without TD Free Public Use of the Invention and Obvious Modifications Thereof 9/10/2015 4

Common Flags: What are they? Represents a Good Practice or Legal Requirement for Proper Double Patenting Prosecution Represents a Potential Issue that Might Need to be Corrected by the PTO or Require Greater Attention by Examiner Represents an Issue that Needs to be Corrected by the PTO 9/10/2015 5

Disclose Information Material to Patentability Disclose any relevant USPTO unpublished applications, published applications and patents to inform the examiner of potential double-patenting references under 37 C.F.R. 1.56 ( Duty of Candor ) Possible DP situations include: Filed by the same inventive entity Filed by different inventive entities having a common joint inventor Filed by at least one Applicant in common who is not a common joint inventor (for AIA cases) Filed by a common assignee Filed by different assignees, but subject to a joint research agreement with each other (pursuant to the CREATE Act for pre-aia first-to-invent cases, or to 35 U.S.C. 102(b)(2)(C) and 102(c) for AIA first inventor-to-file cases) Applicant must provide a copy of each cited pending unpublished U.S. application - 37 CFR 1.98(a)(2)(iii) 9/10/2015 6

Focus on the Claims Claims of the potentially conflicting patent or application versus the examined claims is basis for consideration Use of the specification of potentially conflicting patent or application is generally prohibited Limited exceptions apply to be discussed more fully later 9/10/2015 7

Withdrawn Claims Need to be Considered in Copending Case Withdrawn claims in a reference (copending) application must be considered in a provisional NSDP analysis of elected claims in an application under examination. Withdrawn claims in the case under examination should never be considered in a NSDP rejection 9/10/2015 8

35 U.S.C. 101 (Same Invention) Is the same invention being claimed twice? A reliable test: Is there an embodiment that falls within the scope of one claim, but not the other? Could one claim be literally infringed without literally infringing the other claim? If the answer is yes to either question, then there is no basis for a statutory double patenting rejection. See: MPEP 804(II)(A). 9/10/2015 9

A 35 U.S.C. 101 DP Rejection Requires the Exact Same Scope Venn Diagram Claim of potentially conflicting patent or application Examined claim Examined claim and claim of potentially conflicting patent or application exactly match in scope statutory (35 U.S.C. 101) double patenting appropriate. 9/10/2015 10

35 U.S.C. 101 DP Rejection (continued) Venn Diagram Claim of potentially conflicting patent or application Examined claim Examined claim and claim of potentially conflicting patent or application DO NOT exactly match in scope DO NOT make a statutory (35 U.S.C. 101) double patenting rejection. Perform further analysis to determine whether a rejection on nonstatutory double patenting grounds is appropriate. 9/10/2015 11

A TD will NOT Overcome a 35 U.S.C. 101 Rejection A Terminal Disclaimer (TD) will NOT overcome a 35 U.S.C. 101 Rejection The 35 U.S.C. 101 Statute: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. (Emphasis added) 9/10/2015 12

Nonstatutory Double Patenting: Obviousness Type (ODP) Analogous to 35 U.S.C. 103 analysis Determine the scope and content of the Prior Art Ascertain the differences between the Prior Art and the claim at issue Resolve the level of ordinary skill in the art Evaluate evidence of secondary considerations 9/10/2015 13

Non-statutory DP & Prior Art Non-statutory double patenting is NOT a prior art rejection Patent or co-pending application does NOT need to qualify as prior art Any secondary references used in obviousness analysis should qualify as prior art within the meaning of 35 U.S.C. 102 9/10/2015 14

Example: Method Can Render Product Obvious Claim Under Examination: Claim 1. A compound represented by Formula I. 9/10/2015 15

Method/Product Example (continued) Issued Patent: Same inventors, not prior art to the application being examined. Claim 1. A method for preparing an edible product, comprising adding a compound of Formula I to a natural or commercial edible product. 9/10/2015 16

Method/Product Example (continued) There is no restriction on the record in either application. The compound of formula 1 is required to practice the method of the issued patent. The method of the issued patent should be used to reject the compound of formula 1 under non-statutory double patenting. 9/10/2015 17

Typical Ways to Overcome Nonstatutory DP Rejections Amend Claims to encompass non-obvious subject matter Provide persuasive arguments as to why the current claims are not obvious variants over the co-pending application/patent claims Pursuant to 35 U.S.C. 253, an applicant can disclaim the terminal portion of a patent term by filing an appropriate terminal disclaimer (TD) in the U.S. Patent and Trademark Office. Abandon one of the cases 9/10/2015 18

DP Depends on Filing Date NOT Issue Date Typically a TD is required in the later filed case. See MPEP 1490(VI)(D) If two (or more) pending applications are filed, in each of which a rejection of one claimed invention over the other on the ground of provisional nonstatutory double patenting (ODP) is proper, the provisional ODP rejection will be made in each application. If the provisional ODP rejection is the only rejection remaining in the earlier-filed of the two pending applications, (but the later-filed application is rejectable on other grounds), the examiner should then withdraw the provisional ODP rejection and permit the earlier-filed application to issue as a patent without a terminal disclaimer. If the provisional ODP rejection is the only rejection remaining in the later-filed application, (while the earlier-filed application is rejectable on other grounds), a terminal disclaimer must be required in the later-filed application, before the provisional ODP rejection can be withdrawn. A later issued patent may invalidate an earlier issued patent See Gilead Sciences, Inc. v. Natco Pharma Ltd. (Fed. Cir. 2014) where an earlier filed but later issued patent invalidated a later filed but earlier issued patent using nonstatutory double patenting 9/10/2015 19

2 TDs Needed for Same Day Filing To overcome provisional NSDP rejections absent an effective amendment, where both applications are filed on the same day, the provisional NSDP rejection made in each of the applications should be maintained until showing made that the claims are patentably distinct or filling of a terminal disclaimer in both applications. See MPEP 1490, 1490(VI)(D) for a definition of earlier filed - in summary, the "earlier filed application is the one having the earlier effective U.S. filing date, when taking into account each of the benefit claims under 35 U.S.C. 120, 121, and 365(c); 35 U.S.C. 119(e) and 35 U.S.C. 119(a) (provisional benefit or foreign priority) are NOT taken into account in determining which is the "earlier filed application. 9/10/2015 20

Helpful Reminders for Terminal Disclaimers Common reasons for terminal disclaimer disapproval: Identifies a party who is not the applicant (applies to applications filed on or after 9/16/2012) Signer must be identified as the applicant in the applicant information section of the Application Data Sheet (ADS) Does not include the enforceable only during the period of common ownership clause required by 37 CFR 1.321(c). Does not state the extent of ownership/interest of the person who signed or the extent of the business/organization entity s ownership interest on whose behalf the person signed (37 CFR 1.321(b)(3)). Resubmission should include a corrected/replacement TD 9/10/2015 21

Example: How many TDs should I file? TD needed? Patent B (is CIP of A) Application TD filed in Patent B against A TD filed in application against A Patent A Let us assume that Patents A and B claim obvious variations of the current claims. Let us also assume that there is no 121 shield. Is a TD needed for application over B given fact pattern above? Answer = No,- follow the n-1 rule UNLESS all applications were filed on same day 9/10/2015 22

Proper Uses of Specification Specification can be used in certain circumstances See MPEP 804 II (b)(1) Dictionary for claim terminology Portions of the disclosure which provide support for the claims in the potentially conflicting patent or application to determine whether claims sets represent an obvious variation 9/10/2015 23

In re Basell Poliolefine Italia S.P.A. 89 USPQ2d 1030 (Fed. Cir. 2008) 687 Claims (exam) Copolymerizing (1) -olefin (>C 4 ) 987 Claims (art) Copolymerizing (1) -olefin (C 3-6 ) 987 Specification (2) ethylene (2) any olefin (2) ethylene, propylene, butene [The specification] may be used to learn the meaning of terms and in interpreting the coverage of a claim. In re Basell Poliolefine Italia S.P.A., 89 USPQ2d 1030, 1036 (Fed. Cir. 2008). [T]he specification of the 987 patent itself refers to ethylene, propylene, butene, and other olefins which indicates that those olefins were intended to fall within the meaning of the claims. Id. Thus, a Non-statutory DP rejection of the 687 claims using the 987 claims was proper 9/10/2015 24

In re Basell (cont.) MPEP 804 II (B)(1): Specifications of both the earlier and later commonly owned patents can be used to: Learn the meaning of terms Interpret the coverage of a claim Determine whether claims are obvious variants Thus, even though the 687 claims (claims being examined) were more specific than the 987 claims (prior art) and therefore not necessarily anticipated or obvious in view of those claims, the species of the 687 claims were disclosed in the 987 specification, and thus the 687 claims were not patently distinct from the 987 claims. In re Basell Poliolefine Italia S.P.A. 89 USPQ2d 1030 (Fed. Cir. 2008) 9/10/2015 25

The Specification Can Also be Used to Determine the Utility of a Claimed Compound (1) See Sun Pharmaceutical Industries v. Eli Lilly and Co., 611 F.3d 1381, 1389 (2010) U.S. 4,808,614 ( 614) patent claimed gemcitabine and methods of using gemcitabine for treating viral infections. The patent also disclosed (but did not claim) using these compounds to fight cancer U.S. 5,464,826 ( 826) patent claimed methods of using gemcitabine for treating cancer Brief holding: The asserted claims of the later '826 patent simply claim the anticancer use disclosed in the specification of the '614 patent as a method of use claim. See Pfizer, 518 F.3d at 1363; Geneva, 349 F.3d at 1385. Therefore, we affirm the district court's judgment that the asserted claims, claims 2, 6, and 7, of the '826 patent are invalid for obviousness-type double patenting over the '614 patent. 9/10/2015 26

Double Patenting and 35 U.S.C. 121 The Third Sentence of 35 U.S.C. 121 Provides: A patent issuing on an application with respect to which a requirement for restriction under this section has been made, or on an application filed as a result of such a requirement, shall not be used as a reference either in the Patent and Trademark Office or in the courts against a divisional application or against the original application or any patent issued on either of them, if the divisional application is filed before the issuance of the patent on the other application 9/10/2015 27

Double Patenting and 35 U.S.C. 121 (continued) MPEP 804.01 This apparent nullification of double patenting as a ground of rejection or invalidity in such cases imposes a heavy burden on the Office to guard against erroneous requirements for restrictions where the claims define essentially the same invention in different language and which, if acquiesced in, might result in the issuance of several patents for the same invention. 9/10/2015 28

When Prohibition Under 35 U.S.C. 121 Does Not Apply Two or more applications filed no restriction requirement made (i.e., voluntary divisional) Claims amended such that they are not commensurate with the restriction requirement (i.e., consonance not maintained) Restriction withdrawn (e.g., rejoinder) Restriction (lack of unity) only made in PCT application Claims are directed to identical subject matter 9/10/2015 29

Safe Harbor Requires Maintaining Consonance 35 U.S.C. 121 provides Applicants a safe harbor from ODP rejections However, consonance must be maintained with the original restriction requirement Further, this consonance applied to species elections as well St Jude Medical, Inc. v. Access Closure, Inc., 592 F.3d (Fed Cir. 2013) 9/10/2015 30

Nonstatutory Double Patenting: Anticipation Examined claim A ruler comprising: an elongated member; a groove positioned along the member every inch. Patent Claim A ruler comprising: an elongated member with sliding clamp member; a groove positioned along the member every inch. Examined claim anticipated by patent claim 9/10/2015 31

Nonstatutory Double Patenting: Anticipation Examined Claims are generic to (fully encompassed by) a claim in the potentially conflicting patent or application No Graham v. Deere analysis needed Claim of potentially conflicting patent or application Examined claim ODP-Anticipation Rejection Appropriate. 9/10/2015 32

THANK YOU James Wilson, SPE 1624 (571) 272-0661